Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca respiratory business gets boost from three-drug inhaler results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/28/2019 | 09:19am EDT
FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, England

(Reuters) - Prospects for AstraZeneca respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition.

AstraZeneca said the late-stage ETHOS trial of triple-drug therapy Breztri Aerosphere, formerly known as PT010, helped patients suffering from chronic obstructive pulmonary disease (COPD), in a challenge to Glaxosmithkline Trelegy Ellipta.

Colloquially known as smoker's lung, COPD is a progressively worsening and potentially deadly condition that affects more than 380 million people worldwide, primarily caused by smoking but also by occupational hazards such as air pollution or chemical fumes.

Breztri was shown to lower the risk of a recurrence in flare-ups, or exacerbations, when compared to standard two-drug inhalers, adding to previous evidence https://www.astrazeneca.com/media-centre/press-releases/2018/the-lancet-respiratory-medicine-publishes-first-phase-iii-trial-for-pt010-triple-combination-therapy-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-16092018.html#! that the drug helped those without prior exacerbations.

The British drugmaker is seeking to catch up with domestic rival GlaxoSmithKline Trelegy Ellipta, which generated 156 million pounds in sales from COPD last year.

"We believe the Breztri clinical profile is going to be highly competitive," said Tom Keith Roach, Astra's Vice President for the respiratory therapy area, though more trial readouts were needed for better comparison.

He added there was a broader range of patients for which Breztri was shown to reduce exacerbations and, in addition, two dosage forms of Breztri could in future be available to fine-tune the COPD treatment, if regulators can be convinced.

AstraZeneca also said on Wednesday that the U.S. Food and Drug Administration granted orphan drug status to its Fasenra injection to treat a rare allergic inflammation of the esophagus.

That could pave the way for a faster approval against eosinophilic esophagitis for the drug.

It is already cleared for the treatment of severe asthma, competing with GSK's Nucala and Teva's Cinqair.

(Reporting by Ludwig Burger in Frankfurt and Justin George Varghese in Bengaluru ; Editing by Bernard Orr and Louise Heavens)

By Ludwig Burger and Justin George Varghese

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -0.64% 6729 Delayed Quote.15.31%
GLAXOSMITHKLINE -0.39% 1639.8 Delayed Quote.10.39%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED -2.82% 2515 Delayed Quote.-57.12%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
02:29pTEVA PHARMACEUTICAL INDUSTRIES : to Donate Buprenorphine Naloxone Valued at Abou..
DJ
01:54pTEVA PHARMACEUTICAL INDUSTRIES : Settles Track 1 Opioid Cases and Reaches Agreem..
BU
01:46pDrug companies reach $260 million opioid settlement with Ohio counties, avert..
RE
01:40pDrug companies reach $260 million opioid settlement with Ohio counties, avert..
RE
01:22pWALL STREET STOCK EXCHANGE : Tech stocks drive gains on Wall Street; Boeing weig..
RE
01:14pMARKET SNAPSHOT: Dow Ascent Towards All-time High Clipped By Boeing's Stock S..
DJ
10:20aFour Drug Companies Reach Last-Minute Settlement in Opioid Litigation -- 3rd ..
DJ
10:14aTEVA PHARMACEUTICAL INDUSTRIES : Billion-dollar lawsuits accuse drugmakers, dist..
RE
08:43aFour Drug Companies Reach Last-Minute Settlement in Opioid Litigation -- 2nd ..
DJ
08:42aTEVA PHARMACEUTICAL INDUSTRIES : three U.S. drug distributors reach opioid settl..
RE
More news
Financials (USD)
Sales 2019 17 171 M
EBIT 2019 4 022 M
Net income 2019 -107 M
Debt 2019 25 620 M
Yield 2019 -
P/E ratio 2019 -87,2x
P/E ratio 2020 5,16x
EV / Sales2019 1,97x
EV / Sales2020 1,83x
Capitalization 8 189 M
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 9,40  $
Last Close Price 7,50  $
Spread / Highest target 193%
Spread / Average Target 25,4%
Spread / Lowest Target -20,0%
EPS Revisions
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-57.12%8 189
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.10%198 751